CXCL12 and hepatocellular carcinoma: The TAM-derived PAI-1 then enhances hepatocellular carcinoma (HCC) malignancy through epithelial–mesenchymal transition (EMT), highlighting the CAF/TAM/PAI-1/CXCL12 axis as a potential therapeutic target (35).